Title : Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.

Pub. Date : 2020

PMID : 31990936






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has been shown to decrease serum triglyceride and low-density lipoproteins cholesterol. Triglycerides dipeptidyl peptidase 4 Homo sapiens
2 Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has been shown to decrease serum triglyceride and low-density lipoproteins cholesterol. Triglycerides dipeptidyl peptidase 4 Homo sapiens